Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Other Revenue by Quarter
Other Revenue (Royalties, BARDA Funding & Contract Manufacturing) ($M) ($M)
Regeneron Pharmaceuticals Other Revenue: $310M in Q3 2026, up 56.4% from a year earlier. That is the highest of the 27 quarters on record here.
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Revenue (Royalties, BARDA Funding & Contract Manufacturing) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 310 | +56.4% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2026 | Jun 30, 2026 | 193 | +5.1% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2026 | Mar 31, 2026 | 171 | +109.0% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 239 | +33.0% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 198 | +73.6% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 184 | +76.0% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 81.9 | -29.9% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 179 | -15.6% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 114 | -17.4% | Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2024 | Jun 30, 2024 | 105 | +50.8% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 117 | +0.8% | Form 10-Q (filed 2025-04-29) ↗ |
| Q4 2023 | Dec 31, 2023 | 213 | +66.4% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2023 | Sep 30, 2023 | 138 | +64.3% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 69.3 | +17.1% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 116 | +23.4% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 128 | +48.1% | Form 10-K (filed 2025-02-05) ↗ |
| Q3 2022 | Sep 30, 2022 | 84.2 | -14.9% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 59.2 | +28.7% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 94 | +88.0% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 86.2 | -30.1% | Form 10-K (filed 2024-02-05) ↗ |
| Q3 2021 | Sep 30, 2021 | 99 | -37.6% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 46 | -78.3% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 50 | -20.9% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 123 | – | Form 10-K (filed 2023-02-06) ↗ |
| Q3 2020 | Sep 30, 2020 | 159 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 212 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 63.2 | – | Form 10-Q (filed 2021-05-06) ↗ |
Breakdown
What makes up other Revenue
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Other Revenue ($M), quarterly Q1 2020–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rev-other-total
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?